JP7455067B2 - 内皮細胞因子およびその方法 - Google Patents

内皮細胞因子およびその方法 Download PDF

Info

Publication number
JP7455067B2
JP7455067B2 JP2020550792A JP2020550792A JP7455067B2 JP 7455067 B2 JP7455067 B2 JP 7455067B2 JP 2020550792 A JP2020550792 A JP 2020550792A JP 2020550792 A JP2020550792 A JP 2020550792A JP 7455067 B2 JP7455067 B2 JP 7455067B2
Authority
JP
Japan
Prior art keywords
transcription factor
family
cells
nr2f2
endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518143A (ja
Inventor
レオナルド アイ． ゾーン
エリオット ジェイ． ヘッジドーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2021518143A publication Critical patent/JP2021518143A/ja
Priority to JP2024037742A priority Critical patent/JP7683068B2/ja
Application granted granted Critical
Publication of JP7455067B2 publication Critical patent/JP7455067B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2020550792A 2018-03-23 2019-03-22 内皮細胞因子およびその方法 Active JP7455067B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024037742A JP7683068B2 (ja) 2018-03-23 2024-03-12 内皮細胞因子およびその方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647433P 2018-03-23 2018-03-23
US62/647,433 2018-03-23
PCT/US2019/023637 WO2019183508A1 (en) 2018-03-23 2019-03-22 Endothelial cell factors and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024037742A Division JP7683068B2 (ja) 2018-03-23 2024-03-12 内皮細胞因子およびその方法

Publications (2)

Publication Number Publication Date
JP2021518143A JP2021518143A (ja) 2021-08-02
JP7455067B2 true JP7455067B2 (ja) 2024-03-25

Family

ID=67987596

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550792A Active JP7455067B2 (ja) 2018-03-23 2019-03-22 内皮細胞因子およびその方法
JP2024037742A Active JP7683068B2 (ja) 2018-03-23 2024-03-12 内皮細胞因子およびその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024037742A Active JP7683068B2 (ja) 2018-03-23 2024-03-12 内皮細胞因子およびその方法

Country Status (6)

Country Link
US (2) US12146165B2 (https=)
EP (1) EP3768282A4 (https=)
JP (2) JP7455067B2 (https=)
CN (1) CN112105721A (https=)
CA (1) CA3094837A1 (https=)
WO (1) WO2019183508A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096798A2 (en) * 2023-10-31 2025-05-08 The Children's Medical Center Corporation Endothelial cell factors and methods thereof
CN118834915A (zh) * 2024-08-15 2024-10-25 扬州大学 一种在羊毛乳头细胞中稳定过表达的sox18慢病毒重组标签载体的构建及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201133A2 (en) 2015-06-09 2016-12-15 The Regents Of The University Of California Hematopoietic cells and methods of using and generating the same
WO2017015245A1 (en) 2015-07-20 2017-01-26 Angiocrine Bioscience, Inc. Methods and compositions for stem cell transplantation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042910A2 (en) 2007-09-26 2009-04-02 University Of South Florida Ship inhibition to direct hematopoietic stem cells and induce extramedullary hematopoiesis
US20050227352A1 (en) * 2004-04-09 2005-10-13 Stowers Institute For Medical Research Use of BMP (BAM) signaling to control stem cell fate determination
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US20120207744A1 (en) * 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
US20130243736A1 (en) * 2012-01-27 2013-09-19 Sapporo Medical University Replacement of bone marrow niche cells for treatment of various diseases
GB201212111D0 (en) * 2012-07-06 2012-08-22 Gmbh Vascular bed-specific endothelial cells
US20140162366A1 (en) * 2012-08-31 2014-06-12 Salk Institute For Biological Studies Generation of vascular progenitor cells
US9382531B2 (en) * 2012-10-22 2016-07-05 Wisconsin Alumni Research Foundation Induction of hemogenic endothelium from pluripotent stem cells
JP6581906B2 (ja) * 2013-01-15 2019-09-25 コーネル ユニヴァーシティー 確定因子によるヒト内皮の造血性多系列前駆細胞へのリプログラミング
KR102571649B1 (ko) * 2014-12-19 2023-08-25 앤지오크린 바이오사이언스 인코포레이티드 조작된 내피 세포를 포함하는 생체적합성 임플란트
CN108291196B (zh) * 2015-07-20 2021-08-27 安吉克莱茵生物科学有限公司 表达ets转录因子的工程化的内皮细胞

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201133A2 (en) 2015-06-09 2016-12-15 The Regents Of The University Of California Hematopoietic cells and methods of using and generating the same
WO2017015245A1 (en) 2015-07-20 2017-01-26 Angiocrine Bioscience, Inc. Methods and compositions for stem cell transplantation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. J. Hagedorn, et al.，blood，2017年，V.130(Suppl_1):136

Also Published As

Publication number Publication date
JP2024075624A (ja) 2024-06-04
JP7683068B2 (ja) 2025-05-26
US20240417695A1 (en) 2024-12-19
JP2021518143A (ja) 2021-08-02
WO2019183508A1 (en) 2019-09-26
EP3768282A1 (en) 2021-01-27
CA3094837A1 (en) 2019-09-26
US12146165B2 (en) 2024-11-19
US20210079343A1 (en) 2021-03-18
CN112105721A (zh) 2020-12-18
EP3768282A4 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
Pang et al. Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation
Ellis et al. Targeting tumor angiogenesis with histone deacetylase inhibitors
Yousefi et al. Msi RNA-binding proteins control reserve intestinal stem cell quiescence
Kanda et al. Sall1 maintains nephron progenitors and nascent nephrons by acting as both an activator and a repressor
Wu et al. YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis
Li et al. Histone H4K12 lactylation promotes malignancy progression in triple-negative breast cancer through SLFN5 downregulation
JP7683068B2 (ja) 内皮細胞因子およびその方法
Li et al. Muscle stem cell renewal suppressed by Gas1 can be reversed by GDNF in mice
Qin et al. Topoisomerase IIA in adult NSCs regulates SVZ neurogenesis by transcriptional activation of Usp37
Hagedorn et al. Transcription factor induction of vascular blood stem cell niches in vivo
Lai et al. Spinal RNF20-mediated histone H2B monoubiquitylation regulates mGluR5 transcription for neuropathic allodynia
Schmitt et al. Functional synapses between small cell lung cancer and glutamatergic neurons
Gao et al. Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor‐Trichostatin A through Sp1 binding site
Sharma et al. Role of podoplanin (PDPN) in advancing the progression and metastasis of glioblastoma multiforme (GBM)
Thi Thu et al. Tbx2a is required for specification of endodermal pouches during development of the pharyngeal arches
Maharjan et al. Eya2 is critical for the E2A-HLF-mediated immortalization of mouse hematopoietic stem/progenitor cells
WO2025096798A2 (en) Endothelial cell factors and methods thereof
JPWO2005063301A1 (ja) Ｅｍｔ誘導剤
US9435809B2 (en) Method of treating and reducing the risk of acute myelogenous leukemia
Binhassan PHF6 as a novel interactor of the transcriptional co-regulator LMO2 in T-Cell acute lymphoblastic leukaemia (T-ALL) and myeloid differentiation
CN113215168B (zh) 一种卵巢癌细胞耐药的标志物及其应用
Boone Characterization of FET and ETS domain contributions to fusion oncoprotein activity in Ewing sarcoma
Wang et al. FTO-mediated m6A modification regulates the osteogenic differentiation of ADSCs by targeting FOXO1
Horike et al. Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling
Swadi Characterisation of potential therapeutic molecules for neuroblastoma using chick chorioallantoic membrane xenograft model

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201119

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240312

R150 Certificate of patent or registration of utility model

Ref document number: 7455067

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150